<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786629</url>
  </required_header>
  <id_info>
    <org_study_id>BLI800-480</org_study_id>
    <nct_id>NCT01786629</nct_id>
  </id_info>
  <brief_title>BLI800-480: A Safety and Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects</brief_title>
  <official_title>BLI800-480: A Safety and Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety, tolerance and efficacy of SUPREP Bowel Prep Kit to an FDA approved
      control as bowel preparations prior to colonoscopy in adult patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With a Successful Preparation (Cleaning Rated as &quot;Good&quot; or &quot;Excellent&quot;)</measure>
    <time_frame>Day of colonoscopy</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">338</enrollment>
  <condition>Colonoscopy</condition>
  <condition>Bowel Preparation</condition>
  <condition>Endoscopy</condition>
  <arm_group>
    <arm_group_label>SUPREP Bowel Prep Kit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUPREP Bowel Prep Kit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDA approved bowel preparation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA approved bowel preparation containing electrolytes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUPREP Bowel Prep Kit</intervention_name>
    <description>solution for oral administration prior to colonoscopy</description>
    <arm_group_label>SUPREP Bowel Prep Kit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDA approved bowel preparation containing electrolytes</intervention_name>
    <description>solution for oral administration prior to colonoscopy</description>
    <arm_group_label>FDA approved bowel preparation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female outpatients who are undergoing colonoscopy for a routinely accepted
        indication.

        At least 18 years of age

        If female, and of child-bearing potential, is using an acceptable form of birth control

        Negative urine pregnancy test at screening, if applicable

        In the Investigator's judgment, subject is mentally competent to provide informed consent
        to participate in the study

        Exclusion Criteria:

        Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal
        obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.

        Subjects who had previous significant gastrointestinal surgeries

        Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically
        significant electrolyte abnormalities based on screening laboratory results, such as
        hypernatremia, hyponatremia, hyperphosphatemia, hypokalemia, hypocalcemia, dehydration, or
        those secondary to the use of diuretics or angiotensin converting enzyme (ACE) inhibitors.

        Subjects with a prior history of renal, liver or cardiac insufficiency

        Subjects with impaired consciousness that predisposes them to pulmonary aspiration.

        Subjects undergoing colonoscopy for foreign body removal and/or decompression.

        Subjects who are pregnant or lactating, or intending to become pregnant during the study.

        Subjects of childbearing potential who refuse a pregnancy test.

        Subjects allergic to any preparation components.

        Subjects who, in the opinion of the Investigator, should not be included in the study for
        any reason, including inability to follow study procedures.

        Subjects who have participated in an investigational surgical, drug, or device study within
        the past 30 days.

        Subjects who withdraw consent before completion of Visit 1 procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McGowan, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Braintree Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36693</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Clinical Studies</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Associates</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island GI Research Group</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Gastroenterology Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin Gastroenterology</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <results_first_submitted>July 14, 2014</results_first_submitted>
  <results_first_submitted_qc>July 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2014</results_first_posted>
  <last_update_submitted>August 6, 2014</last_update_submitted>
  <last_update_submitted_qc>August 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Sodium sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SUPREP Bowel Prep Kit</title>
          <description>SUPREP Bowel Prep Kit
SUPREP Bowel Prep Kit: solution for oral administration prior to colonoscopy</description>
        </group>
        <group group_id="P2">
          <title>FDA Approved Bowel Preparation</title>
          <description>FDA approved bowel preparation containing electrolytes
FDA approved bowel preparation containing electrolytes: solution for oral administration prior to colonoscopy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Participants represents the population that was dispensed a preparation and took any portion of the preparation.</population>
      <group_list>
        <group group_id="B1">
          <title>SUPREP Bowel Prep Kit</title>
          <description>SUPREP Bowel Prep Kit
SUPREP Bowel Prep Kit: solution for oral administration prior to colonoscopy</description>
        </group>
        <group group_id="B2">
          <title>FDA Approved Bowel Preparation</title>
          <description>FDA approved bowel preparation containing electrolytes
FDA approved bowel preparation containing electrolytes: solution for oral administration prior to colonoscopy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="169"/>
            <count group_id="B2" value="169"/>
            <count group_id="B3" value="338"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="10.4"/>
                    <measurement group_id="B2" value="57.8" spread="9.6"/>
                    <measurement group_id="B3" value="57.8" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188" spread="39"/>
                    <measurement group_id="B2" value="192" spread="49"/>
                    <measurement group_id="B3" value="190" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With a Successful Preparation (Cleaning Rated as &quot;Good&quot; or &quot;Excellent&quot;)</title>
        <time_frame>Day of colonoscopy</time_frame>
        <population>The analysis population contains subjects that consumed any portion of their bowel preparation. Subject who discontinued from the study for reasons other safety of efficacy are not included (e.g. insurance issues).</population>
        <group_list>
          <group group_id="O1">
            <title>SUPREP Bowel Prep Kit</title>
            <description>SUPREP Bowel Prep Kit
SUPREP Bowel Prep Kit: solution for oral administration prior to colonoscopy</description>
          </group>
          <group group_id="O2">
            <title>FDA Approved Bowel Preparation</title>
            <description>FDA approved bowel preparation containing electrolytes
FDA approved bowel preparation containing electrolytes: solution for oral administration prior to colonoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With a Successful Preparation (Cleaning Rated as &quot;Good&quot; or &quot;Excellent&quot;)</title>
          <population>The analysis population contains subjects that consumed any portion of their bowel preparation. Subject who discontinued from the study for reasons other safety of efficacy are not included (e.g. insurance issues).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events were collected for Preparation Day 1 and Day 2 (Day of Colonoscopy). Serious adverse events were collected for a period of 30 days.</time_frame>
      <desc>Adverse events for stomach cramping, stomach bloating and nausea were documented only if the symptom required an intervention or resulted in discontinuation of the bowel preparation.</desc>
      <group_list>
        <group group_id="E1">
          <title>SUPREP Bowel Prep Kit</title>
          <description>SUPREP Bowel Prep Kit
SUPREP Bowel Prep Kit: solution for oral administration prior to colonoscopy</description>
        </group>
        <group group_id="E2">
          <title>FDA Approved Bowel Preparation</title>
          <description>FDA approved bowel preparation containing electrolytes
FDA approved bowel preparation containing electrolytes: solution for oral administration prior to colonoscopy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 360 days from the time submitted to the sponsor for review. The sponsor cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John McGowan, Director Clinical Research</name_or_title>
      <organization>Braintree Laboratories, Inc.</organization>
      <phone>781-843-2202</phone>
      <email>jmcgowan@braintreelabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

